NeuroSense Therapeutics (NASDAQ:NRSN) Earns “Buy” Rating from D. Boral Capital

NeuroSense Therapeutics (NASDAQ:NRSN)‘s stock had its “buy” rating reaffirmed by equities researchers at D. Boral Capital in a note issued to investors on Monday,Benzinga reports. They currently have a $14.00 price objective on the stock.

Other equities analysts also recently issued reports about the company. Noble Financial upgraded NeuroSense Therapeutics to a “strong-buy” rating in a research note on Tuesday, October 14th. Zacks Research raised NeuroSense Therapeutics to a “hold” rating in a report on Wednesday, October 15th. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of NeuroSense Therapeutics in a research note on Wednesday. Two analysts have rated the stock with a Strong Buy rating, one has given a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $14.00.

NeuroSense Therapeutics Trading Down 5.0%

Shares of NASDAQ NRSN traded down $0.06 during midday trading on Monday, hitting $1.05. The company’s stock had a trading volume of 669,895 shares, compared to its average volume of 347,361. NeuroSense Therapeutics has a 1-year low of $0.80 and a 1-year high of $2.60. The firm’s fifty day moving average price is $1.15 and its 200-day moving average price is $1.46.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the business. Jane Street Group LLC acquired a new position in shares of NeuroSense Therapeutics during the second quarter valued at $54,000. Squarepoint Ops LLC grew its position in NeuroSense Therapeutics by 91.0% in the 3rd quarter. Squarepoint Ops LLC now owns 95,375 shares of the company’s stock valued at $119,000 after buying an additional 45,450 shares in the last quarter. Finally, Two Sigma Investments LP acquired a new position in NeuroSense Therapeutics during the 3rd quarter valued at about $26,000. Institutional investors own 1.04% of the company’s stock.

NeuroSense Therapeutics Company Profile

NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases in the United States and internationally. The company’s lead product is PrimeC, an extended-release oral formulation of a fixed-dose combination of ciprofloxacin and celecoxib, currently under Phase 2b/3 clinical trials for the treatment of amyotrophic lateral sclerosis, and completed Phase 2 clinical trials for the treatment of Alzheimer’s, as well as under preclinical studies for the treatment of Parkinson’s disease.